GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Spruce Biosciences
Spruce Biosciences is a biotech company developing drugs to treat rare endocrine disorders. Its stock price is highly volatile and driven by news about the clinical trials of its lead drug.
Share prices of companies in the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases, such as congenital adrenal hyperplasia. We've categorized it as a Pharmaceutical: Metabolism company. The chart below shows how investors value the orphan disease sector.
Broad Market Index - GURU.Markets
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine disorders. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SPRB - Daily change in the company's share price Spruce Biosciences
Spruce Biosciences, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for rare diseases.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Spruce Biosciences develops drugs to treat rare endocrine diseases. Biotech focused on rare diseases is a volatile niche. The chart below shows the average fluctuations in this sector, allowing you to assess the risks and potential of SPRB shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Spruce Biosciences is a biotech company specializing in the treatment of rare endocrine diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Spruce Biosciences
Spruce Biosciences' year-to-date performance is a story of developing a drug for the treatment of rare endocrine diseases. Its 12-month market capitalization is entirely dependent on clinical trial data. Success of its lead candidate for the treatment of congenital adrenal hyperplasia could be a breakthrough and the first approved therapy.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Spruce, a late-stage biotech company, develops drugs to treat rare endocrine disorders. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Spruce Biosciences, a biopharmaceutical company focused on treating rare endocrine diseases such as congenital adrenal hyperplasia, is an example of a niche player. Its annual market capitalization growth is driven by the success of its single key drug and the needs of a relatively small patient group.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. The data on its drug for treating rare endocrine disorders is a key highlight.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company focused on treating rare endocrine diseases, such as congenital adrenal hyperplasia. Its future depends on the success of clinical trials. The biotech sector's performance reflects investor interest in orphan diseases, providing a backdrop for evaluating Spruce's niche strategy.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Spruce Biosciences, a biopharmaceutical company developing drugs for rare diseases, lives by the laws of science. Its shares are driven by news of trials, and their performance is completely disconnected from overall economic trends, which is typical for biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Spruce Biosciences
Spruce Biosciences, a biotech company developing treatments for rare endocrine diseases, is entirely dependent on clinical data. Its weekly stock price has been a roller coaster, with the price reacting sharply to the publication of research results that will shape the company's future.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company focused on rare endocrine diseases. Its shares, like many in this sector, can experience extreme volatility on clinical trial news. The chart will help separate these events from general market movements.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Spruce Biosciences is a biotech company focused on rare diseases. Its shares can experience extreme volatility on clinical trial news. The chart will help separate these events from overall market movements and show its independent path.
Market capitalization of the company, segment and market as a whole
SPRB - Market capitalization of the company Spruce Biosciences
Spruce Biosciences' market capitalization chart reflects investors' assessment of its focus on treating rare endocrine diseases. Its dynamics reflect the market's confidence in its lead drug, a treatment for congenital adrenal hyperplasia. Its low valuation reflects mixed clinical data and a high stake in the success of future research.
SPRB - Share of the company's market capitalization Spruce Biosciences within the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing a drug for the treatment of rare endocrine diseases. Its market share is small, but it is focused on a high-need area. The company is betting on its lead candidate, tildiserfont, for the treatment of congenital adrenal hyperplasia.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total market capitalization of the entire biotech sector focused on treating metabolic diseases. For Spruce Biosciences, which works on rare endocrine disorders, this line is a "prize fund." Its growth demonstrates how much investors are willing to invest in this complex yet important area of pharmaceuticals.
Market capitalization of all companies included in a broad market index - GURU.Markets
Spruce Biosciences develops drugs to treat rare endocrine disorders. Its market capitalization is the valuation of its research portfolio. It represents the share of the overall market that investors are willing to allocate to finding solutions for patients with hormonal disorders.
Book value capitalization of the company, segment and market as a whole
SPRB - Book value capitalization of the company Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. Its book value represents its financial resources for conducting clinical trials. How has this vital asset changed? The chart below shows this story.
SPRB - Share of the company's book capitalization Spruce Biosciences within the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company focused on rare endocrine diseases. Its scientific activities require a resource base: a laboratory for developing and testing its drugs. The chart shows the company's share of the physical R&D infrastructure in this specific segment.
Market segment balance sheet capitalization - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Spruce focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Spruce Biosciences' assets are not plants, but capital allocated to clinical trials of its lead candidate for the treatment of rare endocrine diseases such as congenital adrenal hyperplasia. These assets represent the financial resources available for these developments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs for rare endocrine disorders. Its market capitalization is a measure of its lead candidate and its potential in this niche but important market.
Market to book capitalization ratio in a market segment - Pharma metabolism
Spruce Biosciences is a biotech company developing drugs to treat rare endocrine diseases. Its high valuation on this chart reflects the success of its lead drug in clinical trials, which is key to its future.
Market to book capitalization ratio for the market as a whole
Spruce Biosciences is working on treatments for rare endocrine diseases. The company's market capitalization reflects investors' hopes that its drugs will be successful. This chart shows how the market values biotech companies targeting orphan (rare) diseases, where drug prices can be very high.
Debts of the company, segment and market as a whole
SPRB - Company debts Spruce Biosciences
Spruce, a biopharmaceutical company developing drugs for rare endocrine diseases, is in the clinical stage and relies entirely on external funding to conduct its trials. This chart illustrates the financial requirements and risks associated with developing drugs for orphan diseases.
Market segment debts - Pharma metabolism
Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing drugs to treat rare endocrine diseases. This chart shows how the company raises capital to fund its expensive and lengthy clinical trials, a standard model for biotech companies working on orphan diseases.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine disorders. Clinical trials in this niche area are lengthy and expensive, with uncertain outcomes. This chart shows how the company uses debt to finance its high-risk, yet important, research.
Market segment debt to market segment book capitalization - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. Clinical trials in this area require significant investment. This chart shows how the company finances its operations, comparing its debt structure to the broader biotech sector.
Debt to book value of all companies in the market
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine disorders. Clinical trials in this area are expensive and time-consuming. How dependent is Spruce on debt financing? This chart of total market debt allows us to assess its financial vulnerability and survival strategy.
P/E of the company, segment and market as a whole
P/E - Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company in late-stage clinical trials focused on developing drugs for rare endocrine disorders. This chart shows how investors value its lead candidate. The valuation is heavily dependent on the results of late-stage trials.
P/E of the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing treatments for rare endocrine diseases, such as congenital adrenal hyperplasia. This chart illustrates the average valuation in the pharmaceutical sector, where investors evaluate the potential of orphan disease drugs, which often have accelerated approval and high price points.
P/E of the market as a whole
Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for rare endocrine diseases. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether SPRB's valuation is based on the potential of its lead candidate or is moving in line with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. Its lead candidate targets congenital adrenal hyperplasia. This chart shows how investors assess the chances of success in this narrow but important therapeutic niche, which shapes future revenue expectations.
%20P%2FE%20Spruce%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Spruce-Biosciences&v=1772513695841 "Chart of the company's future (projected) P/E Spruce Biosciences")
Future (projected) P/E of the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. The chart shows average profitability expectations for the sector. It helps understand how high investors' expectations are for the success of its clinical programs in areas where there is a pressing need for new treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772513695860 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat rare endocrine disorders. This chart of overall risk appetite in the biotech sector shows how willing investors are to fund companies targeting orphan diseases, where the market is small but drug prices can be very high.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513695868 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Spruce Biosciences
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. Its financial performance is based on clinical trial expenses. This chart shows investments in developing therapies for patients with unmet medical needs.
Profit of companies in the market segment - Pharma metabolism
Spruce Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for rare endocrine diseases, such as congenital adrenal hyperplasia. This chart shows overall profitability in the metabolic and endocrine diseases sector, where there is a high need for new therapeutic options for patients.
Overall market profit
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine disorders. Its future depends solely on the success of clinical trials. The need for treatments for these conditions is independent of the economic situation, making the company's business immune to the cycles illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. Future profits depend on the success of its lead candidate in clinical trials. This chart shows analysts' speculative expectations regarding the company's potential in the orphan disease market.
%20profit%20of%20the%20company%20Spruce%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Spruce-Biosciences&v=1772513695936 "Graph of future (projected) profit of the company Spruce Biosciences")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases, such as congenital adrenal hyperplasia. The company's success hinges on the results of its key clinical trial. This chart shows revenue projections for the metabolic diseases sector, providing context for evaluating Spruce's niche strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772513695960 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine disorders. Its future depends on the results of clinical trials. This economic outlook affects investors' overall risk appetite, which is critical for biotech financing.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513695997 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Spruce Biosciences
Spruce Biosciences is a clinical-stage biopharmaceutical company focused on rare endocrine diseases. It has no revenue. This chart reflects solely investor confidence in its scientific developments. Its performance is entirely dependent on clinical trial results.
P/S market segment - Pharma metabolism
Spruce Biosciences is a late-stage biopharmaceutical company developing a novel drug for the treatment of rare endocrine diseases such as congenital adrenal hyperplasia. Their goal is to offer the first approved therapy for these patients. This chart reflects the average revenue estimate for the sector, which helps assess the commercial potential of Spruce's developments.
P/S of the market as a whole
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs for rare endocrine disorders. This chart emphasizes that the valuation of such companies is based on the potential of their developments to address unmet medical needs, not on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Spruce Biosciences
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. Its revenue valuation is crucial for the company. It reflects investor expectations for the success of its lead drug in clinical trials and its potential to become the first approved treatment for certain forms of congenital adrenal hyperplasia.
%20P%2FS%20Spruce%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Spruce-Biosciences&v=1772513696163 "The graph of the company's future (projected) P/S Spruce Biosciences")
Future (projected) P/S of the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs for rare endocrine diseases. Its lead candidate is designed for the treatment of congenital adrenal hyperplasia. This chart shows how investors view the company's future revenue relative to the pharmaceutical sector. It demonstrates the market's confidence in the potential of its drug for this specific patient group.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772513696208 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Spruce Biosciences develops drugs to treat rare endocrine diseases. The company's future depends on the success of its lead candidate in clinical trials. This chart of overall market expectations reflects investor belief that even drugs for rare diseases can become blockbusters due to their high price and lack of alternatives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513696217 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Spruce Biosciences
This chart shows the financial performance of Spruce Biosciences, a clinical-stage biopharmaceutical company developing drugs to treat rare endocrine disorders. Commercial sales revenue is not available, and financial indicators reflect clinical trial costs.
Sales of companies in the market segment - Pharma metabolism
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing drugs for the treatment of rare endocrine diseases. It currently has no sales revenue. Its future revenue is entirely dependent on the success of its lead candidate, tildronepront, in clinical trials.
Overall market sales
Spruce Biosciences is a clinical-stage biopharmaceutical company developing treatments for rare endocrine diseases. Its success depends entirely on the results of clinical trials. This overall market performance chart is irrelevant to the valuation of a company whose value is created in the laboratory and determined by its scientific potential.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. Its lead candidate is designed to treat congenital adrenal hyperplasia. Future revenue is dependent on the success of clinical trials. This chart reflects analyst expectations for the commercial potential of its targeted therapy.
%20sales%20of%20the%20company%20Spruce%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Spruce-Biosciences&v=1772513696369 "Schedule of future (projected) sales of the company Spruce Biosciences")
Future (projected) sales of companies in the market segment - Pharma metabolism
Spruce Biosciences develops drugs to treat rare endocrine disorders. This chart shows the sales forecast for the biotech sector. Do analysts expect the orphan drug market to grow thanks to scientific breakthroughs and regulatory support? This allows us to assess the overall trend for the company.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772513696423 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. Its value and prospects depend solely on the results of clinical trials. The general economic trends reflected in this chart do not affect its scientific activities or patient demand for treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513696465 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Spruce Biosciences
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. This chart reflects its financial performance at the clinical trial stage. Profitability depends on successful trial results and potential approval of its drugs, which target patients with limited or no treatment options.
Market segment marginality - Pharma metabolism
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. This chart reflects its financial position, with profitability entirely dependent on future clinical trial success, regulatory approval, and commercialization of its highly targeted products.
Market marginality as a whole
Spruce Biosciences is an endocrinology biotech company developing drugs for rare diseases. Its future depends on success in clinical trials. This total return chart reflects the investor appetite for risk, which is necessary to fund development in highly specialized medical fields.
Employees in the company, segment and market as a whole
Number of employees in the company Spruce Biosciences
Spruce Biosciences is a clinical-stage biotech company developing drugs for rare endocrine disorders. Its small but highly skilled staff is focused on conducting clinical trials. This graph shows how the team grows as its lead candidate progresses through key development phases.
Share of the company's employees Spruce Biosciences within the market segment - Pharma metabolism
Spruce Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare endocrine diseases. Its team consists of scientists and clinical research specialists. This chart shows the company's market share, reflecting the scale of its clinical programs and its focus on a narrow area of medicine.
Number of employees in the market segment - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases, such as congenital adrenal hyperplasia. The chart illustrates its work in the metabolic pharmaceuticals sector. Its focus on orphan diseases allows the company to address the needs of patients with limited treatment options.
Number of employees in the market as a whole
Spruce Biosciences is a biopharmaceutical company focused on rare endocrine diseases. Its staff consists of scientists and clinicians, and its growth is driven by research progress. This chart shows general trends, and Spruce is an example of a company where employment is driven by a long-term mission to create medicines for patients with limited treatment options.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Spruce Biosciences (SPRB)
Spruce Biosciences is a biotech company focused on rare endocrine diseases, specifically congenital adrenal hyperplasia (CAH). This chart shows how the market values their highly specialized R&D. It reflects the market value per employee, which is a measure of the value of their lead drug candidate.
%20of%20the%20company%20Spruce%20Biosciences%20(SPRB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Spruce-Biosciences-SPRB&v=1772513696633 "Chart of market capitalization per employee (in thousands of dollars) of the company Spruce Biosciences (SPRB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Spruce Biosciences (SPRB) is a biopharmaceutical company developing new treatments for rare endocrine diseases. In this field, the company's market capitalization per employee is a measure of the potential of its drugs. A high value may indicate that the company is targeting diseases for which there are no approved treatments, offering significant commercial potential.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772513696636 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Spruce Biosciences is a biopharmaceutical company developing drugs to treat rare endocrine diseases. Its valuation is based on the potential of its lead candidate. The chart shows a high valuation per employee, as the market sees significant unmet demand in this niche, and a successful drug could become a standard of care.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513696649 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Spruce Biosciences (SPRB)
Spruce Biosciences is a clinical-stage biotech company developing drugs to treat rare endocrine disorders. This chart reflects the R&D workload. A negative R&D workload (loss per employee) is typical for biotech, reflecting the amount of capital invested in each scientist to conduct clinical trials.
%20Chart%20Spruce%20Biosciences%20(SPRB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Spruce-Biosciences-SPRB&v=1772513696655 "Company Profit Per Employee (in thousands of dollars) Chart Spruce Biosciences (SPRB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Spruce Biosciences, Inc. is a biopharmaceutical company developing drugs for rare endocrine diseases. In this niche, efficiency per employee is critical. The graph shows the financial return on a small but highly specialized team, which is an indicator of the potential of their drug candidates.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772513696662 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Spruce Biosciences is a biotech company focused on rare endocrine diseases (e.g., adrenal hyperplasia). It's an R&D company. This chart, showing average market efficiency, provides context for evaluating the biotech model: there's no mass production; all value is created by the intellectual labor of a small group of scientists.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513696676 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Spruce Biosciences (SPRB)
Spruce Biosciences is a biopharmaceutical company focused on rare endocrine diseases. At the clinical stage, revenue per employee can be zero. The graph represents future potential: a successful drug for a rare disease could command a high price, leading to very high revenue per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Spruce-Biosciences-SPRB&v=1772513696692 "Sales chart per company employee Spruce Biosciences (SPRB)")
Sales per employee in the market segment - Pharma metabolism
Spruce Biosciences (SPRB) is a clinical-stage biotech developing drugs for rare endocrine diseases (such as congenital adrenal hyperplasia). They have no commercial revenue. This chart, which reflects average productivity in the sector, serves as a benchmark for Spruce. It demonstrates the efficiency of their R&D personnel expenditures.
Sales per employee for the market as a whole
Spruce Biosciences is a clinical-stage biotech company focused on rare endocrine diseases. Currently, the company has no commercial revenue. This chart reflects their focus on R&D and investment in the team of scientists working on breakthrough drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Spruce Biosciences (SPRB)
Spruce Biosciences (SPRB) develops drugs to treat rare endocrine diseases. This chart tracks short positions. Short positions represent a bet on clinical trial failure. The failure of a single key drug often spells doom for such a highly specialized company.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Spruce-Biosciences-SPRB&v=1772513696722 "Short Shares Chart for the Company Spruce Biosciences (SPRB)")
Shares shorted by market segment - Pharma metabolism
Spruce Biosciences (SPRB) is a biotech company developing oral medications for the treatment of rare endocrine diseases such as congenital adrenal hyperplasia (CAH). This chart aggregates short positions across the biotech sector. It reflects investor skepticism regarding the risks of clinical trials.
Shares shorted by the overall market
Spruce Biosciences is a biotech focused on rare endocrine diseases. This chart illustrates the overall market pessimism. For companies burning through cash on R&D, rising fears mean the window for raising capital is closing. Investors are unwilling to take risks, fearing failure in clinical trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Spruce Biosciences (SPRB)
Spruce Biosciences focuses on rare endocrine diseases like congenital heart disease. It's a complex biotech with a binary outcome. This graph represents the "pulse" of clinical trials. It overheated in anticipation of Phase 3 data and then plummeted when the data proved inconclusive, revealing extreme risks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Spruce-Biosciences-SPRB&v=1772513696757 "RSI 14 indicator chart for the company's stock Spruce Biosciences (SPRB)")
RSI 14 Market Segment - Pharma metabolism
Spruce (SPRB) is a biotech company specializing in rare endocrine diseases, specifically congenital adrenal hyperplasia (CAH). This chart tracks overall sentiment in the Pharma/Metabolism sector. It helps investors understand whether SPRB's performance reflects its niche or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For Spruce Biosciences (SPRB), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SPRB (Spruce Biosciences)
Spruce Biosciences is a biotechnology company developing a new oral drug (Tildacerfont) for the treatment of rare endocrine diseases, primarily congenital adrenal hyperplasia. This chart shows the analysts' speculative average price target, which is based entirely on their assessment of clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SPRB-Spruce-Biosciences&v=1772513696786 "A chart showing analyst consensus forecasts for the expected stock price. SPRB (Spruce Biosciences)")
The difference between the consensus estimate and the actual stock price SPRB (Spruce Biosciences)
Spruce Biosciences (SPRB) is a biotech whose fate hinges on a single R&D pipeline: treatment for a rare endocrine disorder (CHD). This chart shows how far the current share price differs from the "fair" value predicted by analysts. This gap directly reflects Wall Street's assessment of their chances of securing approval for their blockbuster drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SPRB-Spruce-Biosciences&v=1772513696789 "A chart showing the difference between the consensus forecast and the actual stock price. SPRB (Spruce Biosciences)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Spruce Biosciences is a biotech company going all-in. It is developing a drug (Tilderkemag) for the treatment of a rare genetic disorder, congenital adrenal hyperplasia (CAH). This chart reflects analyst expectations across the metabolic pharma sector, demonstrating whether experts believe this R&D approach will be successful.
Analysts' consensus forecast for the overall market share price
Spruce Biosciences is a biotech company developing drugs to treat rare endocrine disorders. This is a high-risk sector, where success depends on clinical trial results. This chart reflects the overall risk appetite in the market. For Spruce, which has yet to generate revenue, the overall analyst optimism (the rising chart) is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Spruce Biosciences
Spruce Biosciences is a biotech company focused on rare endocrine diseases. Their signature product is the R&D of a drug (Tildicerant) for the treatment of congenital adrenal hyperplasia (CAH). This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of FDA approval.
AKIMA Market Segment Index - Pharma metabolism
Spruce Biosciences is a biopharmaceutical company focused on rare endocrine (metabolism) diseases where standard treatments are often unavailable. This narrow focus requires significant R&D investment. This chart allows investors to see how their composite index compares to the sector average, reflecting their relative performance.
The AKIM Index for the overall market
Spruce Biosciences is a biopharmaceutical company developing treatments for rare endocrine diseases (congenital adrenal hyperplasia). This chart, which reflects the market average, provides a macro backdrop. It helps assess how SPRB, a clinical story in endocrinology, compares to overall economic trends.
